4.2 Cch s dng Ung sau khi n Dng theo ch nh ca bc s, cn b y t
Board-certified reproductive endocrinologist and infertility specialist Armando Hernandez-Rey, MD considers the following key factors: Body mass index (BMI) Insulin sensitivity Metabolic markers, such as glucose and lipid levels Overall reproductive goals A good candidate is typically someone with obesity or overweight who has not responded well to lifestyle changes alone and shows signs of metabolic dysfunction [such as weight gain and insulin resistance] commonly seen in PCOS, Dr
One such agonist is L3740
Possible Side Effects : Although rare, mild discomfort at the injection site may occur
The STEP 1 trial reported waist circumference reductions of approximately 9-10 cm with semaglutide 2.4 mg, while the SURMOUNT-1 trial showed reductions of 14-18 cm with tirzepatide, depending on dose
2023, NEJM) showed 20 percent MACE reduction